Compare Inovio Pharmaceuticals Inc (INO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Nuscale Power Corporation trades at $8.49 (market cap $2.76B). The key difference: Nuscale Power Corporation is far larger — about 30.9× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | SMR | |
|---|---|---|
Market Cap | $89.27M | $2.76B |
Sector | Health | Utilities |
52-Week High | $2.87 | $53.43 |
52-Week Low | $1.05 | $7.64 |
Enterprise Value | $60.28M | $1.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company faces severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61M in 2025. Recent earnings misses and high cash burn highlight execution risks, yet analyst consensus suggests 54% upside to a $12.25 price target, with 50% of coverage rating the stock a Buy amid optimism for its small modular reactor technology.
The stock presents a high-risk, high-reward opportunity. Long-term potential hinges on commercializing its nuclear technology, but near-term risks include persistent losses, funding needs, and project delays. Investors must weigh the speculative growth narrative against fundamental weaknesses and high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
